DelveInsight’s “Epidemic Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Epidemic Keratoconjunctivitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Epidemic Keratoconjunctivitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Epidemic Keratoconjunctivitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Epidemic Keratoconjunctivitis: An Overview
Conjunctivitis (pink eye) is an inflammation or infection of the transparent membrane (conjunctiva) that lines the eyelid and covers the white part of the eyeball. When small blood vessels in the conjunctiva become inflamed, they become more visible, and this is what causes the whites of the eyes to appear reddish or pink. Pink eye is commonly caused by a bacterial or viral infection, an allergic reaction, or – in babies – an incompletely opened tear duct
Epidemic keratoconjunctivitis (EKC) is a highly contagious adenoviral infection that causes severe inflammation of the conjunctiva and cornea. Adenovirus serotypes 8, 19, and 37 are commonly found to be associated with EKC and are considered to be a more critical form of adenoviral keratoconjunctivitis because of the adverse consequences it may have on visual acuity.
Epidemic Keratoconjunctivitis Market Key Facts
In 2021, the total incident cases of EKC in the 7MM were found to be 1,820,868. These cases are expected to go down during the study period 2019–2032.
The highest number of cases for EKC was recorded in Japan in 2021 with a total count of 999,087 cases.
There were 7,339,945 cases of viral conjunctivitis in the 7MM in 2021. This number of viral conjunctivitis cases is anticipated to increase during the study period.
There were a total of 597,035 diagnosed cases of EKC in the 7MM in 2021. This total number of diagnosed cases of EKC in the 7MM is anticipated to increase during the study period.
Japan had the highest number of diagnosed EKC cases (501,522 cases) whereas there were 58,033 diagnosed cases of EKC in the United States in 2021.
The Epidemic keratoconjunctivitis market size in the 7MM is expected to reach USD 17.51 million by 2032.
Japan accounted for the highest Epidemic keratoconjunctivitis market size, in comparison to the other major markets in 2021.
Among the EU-5 countries, Germany had the highest market size with USD 0.21 million in 2021.
The US market size of Epidemic keratoconjunctivitis was estimated to be of USD 3.03 million in 2021.
Epidemic Keratoconjunctivitis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Epidemic Keratoconjunctivitis pipeline therapies. It also thoroughly assesses the Epidemic Keratoconjunctivitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Epidemic Keratoconjunctivitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Epidemic Keratoconjunctivitis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Epidemic Keratoconjunctivitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Epidemic Keratoconjunctivitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Epidemic Keratoconjunctivitis Epidemiology, Segmented as –
Total Incident Cases of Viral conjunctivitis in the 7MM from 2019 to 2032
Total Adenovirus D-specific Incident Cases in the 7MM from 2019 to 2032
Total Incident Cases of Epidemic keratoconjunctivitis (EKC) in the 7MM from 2019 to 2032
Total Diagnosed Incident Cases of Epidemic keratoconjunctivitis (EKC) in the 7MM from 2019 to 2032
Epidemic Keratoconjunctivitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Epidemic Keratoconjunctivitis market or expected to be launched during the study period. The analysis covers the Epidemic Keratoconjunctivitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Epidemic Keratoconjunctivitis drugs based on their sale and market share.
The report also covers the Epidemic Keratoconjunctivitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Epidemic Keratoconjunctivitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Epidemic Keratoconjunctivitis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/epidemic-keratoconjunctivitis-market
Epidemic Keratoconjunctivitis Therapeutics Analysis
There are no approved therapies currently available for the treatment of Epidemic keratoconjunctivitis (EKC) and the treatment regimen is mainly based on supportive therapies like artificial tears, cold compresses, topical NSAIDs, topical corticosteroids, topical antihistamines, topical immune-suppressants, ophthalmic antiseptics, and others.
Epidemic Keratoconjunctivitis Companies Actively Working in the Therapeutics Market Include
Basilea Pharmaceutica
Stiefel Laboratories
Regenero
Sanofi
LeoPharma
Japan Tobacco Inc
Incyte Corporation
Asana Biosciences
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Epidemic Keratoconjunctivitis Competitive Intelligence Analysis
4. Epidemic Keratoconjunctivitis Market Overview at a Glance
5. Epidemic Keratoconjunctivitis Disease Background and Overview
6. Epidemic Keratoconjunctivitis Patient Journey
7. Epidemic Keratoconjunctivitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Epidemic Keratoconjunctivitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Epidemic Keratoconjunctivitis Unmet Needs
10. Key Endpoints of Epidemic Keratoconjunctivitis Treatment
11. Epidemic Keratoconjunctivitis Marketed Therapies
12. Epidemic Keratoconjunctivitis Emerging Drugs and Latest Therapeutic Advances
13. Epidemic Keratoconjunctivitis Seven Major Market Analysis
14. Attribute Analysis
15. Epidemic Keratoconjunctivitis Market Outlook (In US, EU5, and Japan)
16. Epidemic Keratoconjunctivitis Companies Active in the Market
17. Epidemic Keratoconjunctivitis Access and Reimbursement Overview
18. KOL Views on the Epidemic Keratoconjunctivitis Market
19. Epidemic Keratoconjunctivitis Market Drivers
20. Epidemic Keratoconjunctivitis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Hemostasis Market
“Hemostasis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hemostasis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hemostasis market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
